Technical Analysis for MLNT - Melinta Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 2.98 -2.93% -0.09
MLNT closed down 2.93 percent on Monday, May 20, 2019, on 69 percent of normal volume. The bears made the stock sink to a new 52-week low. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MLNT trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hammer Candlestick Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Doji - Bullish? Reversal 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%

Older signals for MLNT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Melinta Therapeutics, Inc., formerly Cempra, Inc., is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus and other gram-positive bacteria.
Medical Specialties Pharmaceutical Infectious Diseases Antibiotics Microbiology Healthcare Associated Infections Bacterial Diseases Pathogenic Bacteria Staphylococcus Aureus Community Acquired Bacterial Pneumonia
Is MLNT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 46.0
52 Week Low 2.7
Average Volume 513,100
200-Day Moving Average 11.0972
50-Day Moving Average 4.275
20-Day Moving Average 4.0805
10-Day Moving Average 3.609
Average True Range 0.3881
ADX 23.82
+DI 14.3194
-DI 34.75
Chandelier Exit (Long, 3 ATRs ) 3.7257
Chandelier Exit (Short, 3 ATRs ) 3.8643
Upper Bollinger Band 5.4199
Lower Bollinger Band 2.7411
Percent B (%b) 0.09
BandWidth 65.648818
MACD Line -0.388
MACD Signal Line -0.247
MACD Histogram -0.141
Fundamentals Value
Market Cap 156.47 Million
Num Shares 52.5 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -1.58
Price-to-Sales 6.92
Price-to-Book 0.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.52
Resistance 3 (R3) 3.49 3.27 3.43
Resistance 2 (R2) 3.27 3.14 3.29 3.40
Resistance 1 (R1) 3.13 3.05 3.02 3.16 3.37
Pivot Point 2.91 2.91 2.86 2.93 2.91
Support 1 (S1) 2.77 2.78 2.66 2.80 2.59
Support 2 (S2) 2.55 2.69 2.57 2.56
Support 3 (S3) 2.41 2.55 2.53
Support 4 (S4) 2.44